Park, Howard Y.
Zoller, Stephen D.
Hegde, Vishal
Sheppard, William
Burke, Zachary
Blumstein, Gideon
Hamad, Christopher
Sprague, Marina
Hoang, John
Smith, Ryan
Romero Pastrana, Francisco
Czupryna, Julie
Miller, Lloyd S.
López-Álvarez, Marina
Bispo, Mafalda
van Oosten, Marleen
van Dijl, Jan Maarten
Francis, Kevin P.
Bernthal, Nicholas M.
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR059033, T32AR059033, 5K08AR069112-01)
CEC MSCI-ITN (713660, 713660)
Article History
Received: 28 February 2020
Accepted: 17 November 2020
First Online: 15 January 2021
Competing interests
: L.S.M. reports that he has grant support from MedImmune, Pfizer, Moderna Therapeutics, Regeneron Pharmaceuticals, Boehringer Ingelheim and consulting fees from Integrated BioTherapeutics outside this study but related to <i>Staphylococcus aureus</i> vaccines and therapeutics. M.L.A., M.B. and M.v.O. report that they have no competing interests relevant to this study. J.M.vD. reports that he has the following competing interests relevant to this study: he has filed a patent application on the use of 1D9, which is owned by his employer University Medical Center Groningen. K.P.F. reports that he is an employee of PerkinElmer, Inc., manufacturer of optical and PET imaging equipment. N.M.B. reports that he has consulting fees from Biomet, Bone Support, Daiichi Sankyo, and Onkos, and he is a board or committee member of the Musculoskeletal Tumor Society and Orthopaedic Research and Education Foundation. The remaining authors declare no competing interests.